Interventions of Cetrorelix Acetate in Estrogen Beta Receptor Expression and Histopathology in Rats Oviduct

Ovarian hypofunction is pathologic conditions where is the ovary being abnormal. The abnormality of the ovary can be induced by the abnormality of the endocrine that regulates the development of the ovary such as, follicle-stimulating hormone (FSH) and luteinizing hormone LH. The production of FSH and LH in the pituitary is determined with the Gonadotropin hormone (GnRH) stimulation. Development of rat ovarian hypofunction models can be performed with the induction of cetrorelix acetate which has an antagonist effect of GnRH. This research was conduct to know the effect of induction of cetrorelix acetate on rat oviduct estrogen beta receptor expression and histopathology. The study used three groups of female rats (Wistar strain) 8-10 weeks old and 150-180 gram weight, each group consisting of six rats. The first group (control) without cetrorelix acetate, the second group treated with cetrorelix acetate 0.009 mg/kg BW and the third group treated with cetrorelix acetate 0.0135 mg/kg BW. Observations of estrogen beta receptor expressions (ERs β) are carried out with immunochemical methods, while observations of histopathological changes of oviduct carried out by Hematocsilin-Eosin (HE stain). The results obtained indicate a significant difference from the administration of the GnRH antagonists in the three treatment groups, among others, the largest reduction of the expression of the estrogen receptor of the ES β by 59.2%, as well as the thinning of the fallopian tubes and the reduced cilia. The conclusion of the study was Cetrorelix acetate as a GnRH antagonist capable of lowering the beta estrogen receptor expression and reducing the number of cilia as well as the viscosity of the wall lining of the fallopian tubes.